Once-daily budesonide MMX in active, mild-to-moderate ulcerative colitis: results from the randomised CORE II study

OBJECTIVE: Budesonide MMX is a novel oral formulation of budesonide that uses Multi-Matrix System (MMX) technology to extend release to the colon. This study compared the efficacy of budesonide MMX with placebo in patients with active, mild-to-moderate ulcerative colitis (UC). DESIGN: Patients were...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Asıl Yazarlar: Travis, Simon P L, Danese, Silvio, Kupcinskas, Limas, Alexeeva, Olga, D'Haens, Geert, Gibson, Peter R, Moro, Luigi, Jones, Richard, Ballard, E David, Masure, Johan, Rossini, Matteo, Sandborn, William J
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: BMJ Publishing Group 2014
Konular:
Inflammatory Bowel Disease
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC3933176/
https://ncbi.nlm.nih.gov/pubmed/23436336
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/gutjnl-2012-304258
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller